• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$48.48 $0.44 (0.92%)

REAL-TIME: Last trade at

Valeant Pharmaceuticals Intern...

NYSE:VRX

Jump to this page for:

Related Resources

Valeant Pharmaceuticals to Acquire Certain Assets from Swiss Herbal

5/24/2012 by Pharmaceutical Processing

Critical Alerts For Corning, Expedia, Agnico Eagle Mines, Brinker International, and Valeant Pharmaceutical Released By InvestorsObserver

5/24/2012 by PR Newswire

Valeant Pharma (VRX) Will Buy Swiss Herbal Remedies

5/24/2012 by StreetInsider.com

Valeant agrees to acquire certain assets from Swiss Herbal

5/24/2012 by Theflyonthewall.com

Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal

5/24/2012 by PR Newswire

Valeant Pharmaceuticals International is Now Oversold

5/23/2012 by Forbes

Valeant Pharmaceuticals - Aggressive Growth

5/23/2012 by NASDAQ

Valeant Pharmaceuticals - Aggressive Growth

5/23/2012 by Zacks Investment Research

2 Stocks With Great Insider-Buying Trends

5/22/2012 by Seeking Alpha

Meda Cash Flow Invites Pipeline Deal at 95% Discount: Real M&A

5/21/2012 by Bloomberg.com

5 Stocks That Insiders Love Right Now

5/16/2012 by TheStreet.com

Stocks End Mixed After Seesaw Session; Europe Weighs

5/7/2012 by Investor's Business Daily

5 Biotech Stocks With Massive Upside Potential In 2013

5/7/2012 by Seeking Alpha

Valeant Beats, Raises EPS Outlook - Analyst Blog

5/7/2012 by Zacks Investment Research

Valeant Beats, Raises EPS Outlook

5/7/2012 by Zacks Equity Research Analyst Blog

Valeant sell-off a buying opportunity, says Susquehanna

5/4/2012 by Theflyonthewall.com

Valeant shares defended at UBS

5/3/2012 by Theflyonthewall.com

CRT Capital Cuts Valeant Pharma (VRX) to Fairly Valued

5/3/2012 by StreetInsider.com

Valeant downgraded to Fair Value from Buy at CRT Capital

5/3/2012 by Theflyonthewall.com

Valeant shares defended at Jefferies

5/3/2012 by Theflyonthewall.com

Valeant: A Risky Bet For Brave Investors

5/3/2012 by Seeking Alpha

Activist Shorts Austerity, Goes Long M&A

5/3/2012 by TheStreet.com

Valeant posts 1Q loss on dermatology deal costs

5/3/2012 by Pharmaceutical Processing

Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results

5/3/2012 by Genetic Engineering News

Valeant to acquire acne medicine, posts Q1 loss due to variety of factors

5/3/2012 by Canadian Business - Canada

Valeant boosts full-year outlook

5/3/2012 by MarketWatch

Valeant loses $12.92-million in Q1

5/3/2012 by StockWatch

Valeant agrees to acquire AcneFree and assets from University Medical

5/3/2012 by Theflyonthewall.com

Valeant Pharmaceuticals (VRX) Posts Q1 EPS of 99c; Boosts FY12 Outlook

5/3/2012 by StreetInsider.com

Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical

5/3/2012 by StockWatch

Pfizer: Stable Long-Term Income Stock With Headwinds Likely In The Interim

5/2/2012 by Seeking Alpha

These Topnotch Funds Are Banking on Buffett

5/2/2012 by Morningstar

Valeant Earnings Expected To Soar As Buyouts Pay Off

5/2/2012 by Investor's Business Daily

Valeant: Why Investors Are Getting In Now

5/1/2012 by Seeking Alpha

Keryx: 22% Gain May Spark More Growth After Successful Zerenex Trial

5/1/2012 by Seeking Alpha

Valeant Pharmaceuticals To Webcast 2012 Annual Meeting Of Shareholders

4/30/2012 by StockWatch

Valeant Pharmaceuticals To Webcast 2012 Annual Meeting Of Shareholders

4/30/2012 by PR Newswire

Valeant Pharmaceuticals to Present at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference

4/27/2012 by StockHouse

Valeant Pharmaceuticals to Present at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference

4/27/2012 by StockWatch

Valeant Pharmaceuticals to Present at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference

4/27/2012 by PR Newswire
See More Articles...